Curative Biotechnology, Inc. (CUBT)

Market Cap	8.47M -17.7%
Revenue (ttm)	n/a
Net Income	-2.84M
EPS	-0.00
Shares Out	1.07B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,800
Average Volume	94,636
Open	0.0074
Previous Close	0.0072
Day's Range	0.0074 - 0.0074
52-Week Range	0.0030 - 0.0288
Beta	1.41
RSI	58.94
Earnings Date	Apr 15, 2026

About Curative Biotechnology

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: CUBT